Effects of pioglitazone mediated activation of PPAR-γ on CIDEC and obesity related changes in mice

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Shamsi, Bilal Haider ^a   Ma, Chaofeng ^b   Naqvi, Saima ^a   Xiao, Yanfeng ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b Center for Disease Control and Prevention (CDC)   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DEATH INDUCING DFFA LIKE EFFECTOR C; GLUCOSE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROTEIN; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; FAT-SPECIFIC PROTEIN 27, MOUSE; GLUCOSE BLOOD LEVEL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY HEIGHT; BODY WEIGHT; CIDEC GENE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE MICROSCOPY; GENE; GENE ACTIVATION; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIPID DIET; LIPOLYSIS; MOUSE; NONHUMAN; OBESITY; PPAR GAMMA GENE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SUBCUTANEOUS FAT; ANIMAL; BIOSYNTHESIS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PATHOLOGY;

MUS;

ANIMALS; BLOOD GLUCOSE; DIET, HIGH-FAT; GENE EXPRESSION REGULATION; HUMANS; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; LIPOLYSIS; MICE; OBESITY; PPAR GAMMA; PROTEINS; SUBCUTANEOUS FAT; THIAZOLIDINEDIONES;

EID: 84907486775     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106992     Document Type: Article

References (36)

1. Hubert HB, Feinleib M, McNamara PM, Castelli WP (1983) Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 67: 968-977.
2. Caballero B (2007) The global epidemic of obesity: an overview. Epidemiologic reviews 29: 1-5.
3. Barabási A-L (2007) Network medicine-from obesity to the "diseasome". New England Journal of Medicine 357: 404-407.
4. Winer S, Chan Y, Paltser G, Truong D, Tsui H, et al. (2009) Normalization of obesity-associated insulin resistance through immunotherapy. Nature medicine 15: 921-929.
5. Jeanrenaud B (1979) Insulin and obesity. Diabetologsia 17: 133-138.
6. Steinberger J, Daniels SR (2003) Obesity, insulin resistance, diabetes, and cardiovascular risk in children: an American Heart Association scientific statement from the Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young) and the Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism). Circulation 107: 1448-1453.
7. Bergman RN, Ader M (2000) Free fatty acids and pathogenesis of type 2 diabetes mellitus. Trends in Endocrinology & Metabolism 11: 351-356.
8. Menon V, Zhi X, Hossain T, Bartke A, Spong A, et al. (2014) The contribution of visceral fat to improved insulin signaling in Ames dwarf mice. Aging cell 13: 497-506.
9. Masternak MM, Bartke A, Wang F, Spong A, Gesing A, et al. (2012) Metabolic effects of intra-abdominal fat in GHRKO mice. Aging cell 11: 73-81.
10. Kawai M, Rosen CJ (2010) PPARγ: a circadian transcription factor in adipogenesis and osteogenesis. Nature Reviews Endocrinology 6: 629-636.
11. Tseng Y-H, Ueki K, Kriauciunas KM, Kahn CR (2002) Differential roles of insulin receptor substrates in the anti-apoptotic function of insulin-like growth factor-1 and insulin. Journal of Biological Chemistry 277: 31601-31611.
12. Traini M, Jessup W (2009) Lipid droplets and adipose metabolism: a novel role for FSP27/CIDEC. Current opinion in lip idology 20: 147-149.
13. Kim Y-J, Cho SY, Yun CH, Moon YS, Lee TR, et al. (2008) Transcriptional activation of Cidec by PPARγ2 in adipocyte. Biochemical and biophysical research communications 377: 297-302.
14. Gong J, Sun Z, Li P (2009) CIDE proteins and metabolic disorders. Current opinion in lipidology 20: 121-126.
15. Rogue A, Spire C, Brun M, Claude N, Guillouzo A (2010) Gene expression changes induced by PPAR gamma agonists in animal and human liver. PPAR research 2010.
16. Puri V, Ranjit S, Konda S, Nicoloro SM, Straubhaar J, et al. (2008) Cidea is associated with lipid droplets and insulin sensitivity in humans. Proceedings of the National Academy of Sciences 105: 7833-7838.
17. Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, et al. (2013) PPAR [gamma] signaling and metabolism: the good, the bad and the future. Nature medicine 99: 557-566.
18. Wang C-Y, Liao JK (2012) A mouse model of diet-induced obesity and insulin resistance. mTOR: Springer, pp. 421-4-33.
19. Bastard J-P, Jardel C, Bruckert E, Blondy P, Capeau J, et al. (2000) Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. Journal of Clinical Endocrinology & Metabolism 85: 3338-3342.
20. Muller PY, Janoyjak H, Miserez AR, Dobbie Z (2002) Processing of gene expression data generated by quantitative real-time RT-PCR. Biotechniques 32:1372-1374, 1376, 1378-1379.
21. Hotta K, Funahashi T, Bodkin NL, Ortmeyer HK, Arita Y, et al. (2001) Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 50: 1126-1133.
22. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, et al. (2008) Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57: 1470 -1481.
23. Kersten S (2001) Mechanisms of nutritional and hormonal regulation of lipogenesis. EMBO reports 2: 282-286.
24. Kageyama H, Hirano T, Okada K, Ebara T, Kageyama A, et al. (2003) Lipoprotein lipase mRNA in white adipose tissue but not in skeletal muscle is increased by pioglitazone through PPAR-γ. Biochemical and biophysical research communications 305: 22-27.
25. Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, et al. (2008) Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 135: 1176-1184.
26. Bergman RN, Kim SP, Catalano KJ, Hsu IR, Chiu JD, et al. (2006) Why visceral fat is bad: mechanisms of the metabolic syndrome. Obesity 14: 16S-19S.
27. Kahn SE, Hull RE, Utzschneider KM (2006) Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444: 840 -846.
28. Felber J, Golay A (2002) Pathways from obesity to diabetes. International journal of obesity and related metabolic disorders: journal of the International Association for the Study of Obesity 26: S39-45.
29. DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, et al. (2011) Pioglitazone for diabetes prevention in impaired glucose tolerance. New England Journal of Medicine 364: 1104-1115.
30. Grygiel-Górniak B (2014) Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications-a review. Nutrition journal 13: 17.
31. Kim YJ, Cho SY, Yun CH, Moon YS, Lee TR, et al. (2008) Transcriptional activation of Cidec by PPARgamma2 in adipocyte. Biochem Biophys Res Commun 377: 297-302.
32. Tanabe Y, Koga M, Saito M, Matsunaga Y, Nakayama K (2004) Inhibition of adipocyte differentiation by mechanical stretching through ERK-mediated downregulation of PPARγ2. Journal of cell science 117: 3605-3614.
33. Chen L, Necela BM, Su W, Yanagisawa M, Anastasiadis PZ, et al. (2006) Peroxisome proliferator-activated receptor γ promotes epithelial to mesenchy- mal transformation by Rho GTPase-dependent activation of ERKI/2. Journal of Biological Chemistry 281: 24575-24587.
34. Flach RJR, Zhang L, Qin H, Bennett A (2011) Loss of MAP kinase phosphatase1 1 from hepatic steatosis by repression of CIDEC/fat-specific protein 27.Journal of Biological Chemistry 286(25): 22195-22202.
35. Gerhold DL, Liu F, Jiang G, Li Z, Xu J, et al. (2002) Gene expression profile of adipocyte differentiation and its regulation by peroxisome proliferator-activated receptor-γ agonists. Endocrinology 143: 2106-2118.
36. Moreno-Navarrete J, Ortega F, Serrano M, Rodriguez-Hermosa J, Ricart W, et al. (2013) CIDEC/FSP27 and PTINI gene expression run in parallel to mitochondrial genes in human adipose tissue, both increasing after weight loss. International Journal of Obesity. doi: 10.1038/ijo.2013.171.